Interleukin-1-alpha targeting antibody - XBiotech
Alternative Names: anti-interleukin-1-alpha (IL-1α), human IgG1 monoclonal antibody; anti-interleukine-1alpha True Human™ Antibody - XBiotech; Hutrukin™Latest Information Update: 28 Jan 2026
At a glance
- Originator XBiotech
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Interleukin 1 alpha inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Stroke
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for phase-I development in Stroke(In volunteers) in USA (IV, Infusion)
- 31 Dec 2024 XBiotech put on hold the planned phase II trial in Stroke
- 28 May 2024 No recent reports of development identified for research development in Inflammation in USA (Parenteral)